Efficacy of treatment with a basal-prandial insulin regimen in patients with type 2 diabetes mellitus previously treated with premixed insulin

被引:1
|
作者
Javier Garcia-Soidan, Francisco [1 ]
机构
[1] Ctr Salud Porrino, Pontevedra, Spain
来源
AVANCES EN DIABETOLOGIA | 2013年 / 29卷 / 01期
关键词
Type 2 diabetes mellitus; Premixed insulin; Basal-prandial therapy; Glycaemic control; Primary health care;
D O I
10.1016/j.avdiab.2013.01.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Premixed insulins are a common treatment for type 2 diabetes mellitus (DM). However, their limitations and the lack of achieving glycaemic control in some patients reinforce the need to find therapeutic alternatives. Objectives: To assess whether basal-prandial therapy (basal insulin, and additional pre-prandial rapid insulin boluses, when required) improves glycaemic control in patients with type 2 DM and glycosylated haemoglobin (HbA1c) >53 mmol/mol (7%) treated with premixed insulin in the primary care setting. Material and methods: A retrospective observational study in which 116 patients with type 2 DM switched from premixed insulin to basal-prandial therapy. Data on demographics, anthropo-metrics, laboratory results, and antidiabetic treatment were collected from the medical charts of the patients, prior to switching the treatment (baseline) and 4 months thereafter. Results: HbA1c significantly decreased from baseline to month 4 (65.1 +/- 5.7 mmol/mol [8.1 +/- 0.5%] versus 51.9 +/- 7.2 mmol/mol [6.9 +/- 0.7%]; p < .005), and 70 patients (60.9%) had an HbA1c <= 53 mmol/mol (7%). Additionally, fasting blood glucose (FBG) significantly decreased (9.7 +/- 1.7 mmol/l [175.4 +/- 31.2 mg/dl] versus 6.9 +/- 1.4 mmol/l [124.4 +/- 25.8 mg/dl]; p < .005), and the number of patients with FBG < 5.6 mmol/l (100 mg/dl) (2 patients [1.7%] versus 21 patients [18.3%]; p < .005), and with post-prandial blood glucose <= 10 mmol/l (180 mg/dl) (14 patients, [12.1%] versus 87 patients [76.3%]; p < .05) significantly increased. There were also significant decreases in body weight (76.3 +/- 12.9 kg versus 74.8 +/- 12.5 kg; p < .001) and waist circumference (96.1 +/- 16.0 cm versus 94.4 +/- 14.5 cm; p < .005). Only 4 patients (3.5%) had hypoglycaemia. Conclusions: Basal-prandial therapy improved glycaemic control in patients with type 2 DM, with a low incidence of hypoglycaemia, and decreased body weight. (C) 2012 Sociedad Espanola de Diabetes. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:12 / 18
页数:7
相关论文
共 50 条
  • [31] INTENSIFICATION OF BASAL INSULIN TREATMENT AMONG PATIENTS WITH DIABETES MELLITUS TYPE 2 IN THE NETHERLANDS
    Overbeek, J.
    Houben, E.
    Kring, S.
    Sommer, J.
    Penning-van Beest, F.
    van der Heijden, A.
    Nijpels, G.
    Herings, R.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A617 - A617
  • [32] THE EFFICACY OF SITAGLIPTIN ON INSULIN TREATMENT FOR JAPANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Matsuhashi, Y.
    Chikazawa, S.
    Matsui, J.
    Daimon, M.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S142 - S142
  • [33] Intensification of Basal Insulin Treatment Among Patients with Type 2 Diabetes Mellitus in the Netherlands
    Overbeek, Jetty A.
    Houben, Eline
    Kring, Sofia I.
    Briers, Jonathan
    Beest, Fernie J. A. Penning-van
    Van der Heijden, Amber A. W. A.
    Nijpels, Giel
    Herings, Ron M. C.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 77 - 77
  • [34] Role of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: A narrative review
    Elizarova, Svetlana
    Galstyan, Gagik R.
    Wolffenbuttel, Bruce H. R.
    [J]. JOURNAL OF DIABETES, 2014, 6 (02) : 100 - 110
  • [35] New strategies for basal insulin treatment in type 2 diabetes mellitus
    Dailey, G
    [J]. CLINICAL THERAPEUTICS, 2004, 26 (06) : 889 - 901
  • [36] Risk of Acute Myocardial Infarction in Patients with Diabetes Mellitus Type 2 Treated with Basal Insulin
    Behr, Sigrid
    Kollhorst, Bianca
    Enders, Dirk
    Timmer, Antje
    Dippel, Franz-Werner
    Theobald, Karlheinz
    Garbe, Edeltraut
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 200 - 201
  • [37] Assessment of basal insulin requirement using fasting tests in insulin-treated patients with type 2 diabetes mellitus
    Wiesli, P.
    Lehmann, R.
    Krayenbuehl, P-A.
    Schmid, C.
    Spinas, G. A.
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2006, 114 (10) : 539 - 543
  • [38] Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus
    Janka, Hans U.
    Plewe, Gerd
    Busch, Klaus
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (02) : 182 - 188
  • [39] Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus: Using insulin glargine as basal insulin
    Kawamori, Ryuzo
    Kadowaki, Takashi
    Ishii, Hitoshi
    Iwasaki, Manabu
    Iwamoto, Yasuhiko
    [J]. DIABETES, 2008, 57 : A573 - A573
  • [40] The Effectiveness of Basal Plus Compared with Premixed Insulin in Insulin-Naive Type 2 Diabetes Patients
    Raghavan, Arun
    Nanditha, Arun
    Satheesh, Krishnamoorthy
    Snehalatha, Chamukuttan
    Seeli, Abraham Catherin
    Simon, Mary
    Susairaj, Priscilla
    Ramachandran, Ambady
    [J]. DIABETES, 2019, 68